Gapping up
In reaction to earnings/guidance:
- HIMS +15.5%, SKIN +13.9%, MELI +10.4%, CDNS +10.1%, NU +8.6%, OSTK +8.4%, PANW +7.7%, LL +7.3%, STLA +6.9%, HCC +6.8%, INDI +5.7%, RRC +5.3% (also reinstates dividend, authorizes $500 mln share repurchase program), BCS +5.2%, OMI +5%, CZR +4.8%, SPCE +4.3%, PCOR +4.2%, PLAB +4%, MAXR +3.6%, TXRH +3.2%, SPT +3.2%, LOW +3.1%, CWH +3%, BWXT +2.9%, GKOS +2.9%, EPR +2.8%, VNOM +2.7% (also increases dividend), RNG +2.5%, TBLA +1.9%, RDN +1.9%, KTOS +1.7%, CLH +1.7%, CUTR +1.6%, GIL +1.6%, LPI +1.5%, O +1.5%, VRSK +1.4%, ESI +1.3%, FANG +1.2% (also increases dividend; also announces a series of leadership appointments and promotions), HFC +1.2%, TOL +0.9%
Other news:
- TEN +93.1% (agrees to be acquired by Apollo (APO) funds for purchase price of $20.00/share in cash)
- MYNZ +13.3% (provides U.S. regulatory review update for ColoAlert)
- RLMD +12.8% (top-line results of study evaluating REL-1017 vs ketamine for abuse potential)
- EVR +2.7% (authorized a share repurchase program of up to the lesser of $1.4 bln or 10 mln shares of Evercore Inc. Class A common stock and/or Evercore LP Units)
- FUV +2.6% (begins operations in new RAMP manufacturing facility in Oregon)
- STRL +2% (awarded $160 mln in projects during Q4 in Specialty Services segment)
- SNY +1.9% (Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine)
- GSK +1.8% (Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine)
- MRNA +1.4% (announces distribution agreement covering Latin America)
- PANL +1.4% (names new COO)
Analyst comments:
- OLPX +6.3% (upgraded to Buy from Hold at Jefferies)
- ARCO +2.1% (upgraded to Outperform from Neutral at Credit Suisse)
- FLR +2% (upgraded to Outperform from Neutral at Robert W. Baird)
- NYMT +1.7% (upgraded to Outperform from Mkt Perform at Keefe Bruyette)
- INTC +1.4% (upgraded to Mkt Perform from Underperform at Raymond James)